Navigation Links
Glivec the hot cancer drug from Novartis

Novartis is the world's sixth-largest drugmaker (by sales).
Novartis was formed after merger of two Swiss companies, Sandoz Ltd. and Ciba-Geigy."Novartis is emerging as one of the premier powerhouses in the global pharmaceuticals industry," says Richard R. Stover, senior analyst with brokerage Natexis Bleichroeder Inc. in New York. The new cancer drug, Glivec's success led to Novartis reported a 24% jump in first-quarter operating earnings, to $1.4 billion, on sales of $5.7 billion. The stock has climbed 15% since mid-March and continues to outperform the industry.

Glivec was first approved for treatment of chronic myeloid leukemia. It is the first treatment ever proven drug to cause certain types of tumors to disappear. While other cancer drugs killsoff healthy cells along with sick ones, Glivec interfere with the proteins that cause tumors to grow. Glivec also is used to treat other rare types of cancer such as gastrointestinal stromal tumors (GIST) and is now being tested in combination with other drugs in fighting prostate cancer.

Glivec was introduced in the U.S. in 2001 under the brand name Gleevec. Sales rose more than 300% in 2002, and could hit the $1 billion mark by the end of this year. Although an annual course of Glivec can cost as much as $25,000, demand for the drug took off so quickly that Novartis was forced to run its production line around the clock.

Since the year 2000 Novartis has launched 10 drugs and this is three times more than its nearest rival. Another 15 are expected to debut by 2006. Among the current crop are Zelmac, a drug for irritable-bowel syndrome;eczema treatment Elidel; and Zometa, a treatment for bone metastases.
'"/>




Page: 1

Related medicine news :

1. Glivec - New Hope For CMC Patients
2. Glivec Enhances Survival Rates In Leukemia
3. Vitamin B12 can help in detecting cancers
4. Want skin cancer? Please have a cigarette
5. New hope for cancer victims – will vaccine cure the deadly bug
6. Clintons new problem - Is the outgoing American president suffering from skin cancer?
7. Are cancer patients being taken for a ride?
8. Breast cancer treatment to be determined by gene test
9. Ductal lavage may detect early breast cancer
10. Beware of the oral patch! It could be cancer!!!
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: